Molecular pathology of non-small cell carcinoma

被引:11
|
作者
Yatabe, Yasushi [1 ,2 ]
机构
[1] Natl Canc Ctr, Dept Diagnost Pathol, Tokyo, Japan
[2] Natl Canc Ctr, Dept Diagnost Pathol, 5-1-1 Tsukiji, Chuo Ku, Tokyo 1040045, Japan
基金
日本学术振兴会;
关键词
immune check-point inhibitors; lung cancer; molecular pathogenesis; oncogene addiction; two-compartment model; FACTOR-RECEPTOR GENE; IMMUNE CHECKPOINT INHIBITORS; TUMOR MUTATION BURDEN; LUNG-CANCER; EGFR MUTATIONS; TYROSINE KINASE; CLINICOPATHOLOGICAL FEATURES; RET REARRANGEMENTS; CLINICAL-FEATURES; PD-L1; EXPRESSION;
D O I
10.1111/his.15080
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Currently, lung cancer is treated by the highest number of therapeutic options and the benefits are based on multiple large-scale sequencing studies, translational research and new drug development, which has promoted our understanding of the molecular pathology of lung cancer. According to the driver alterations, different characteristics have been revealed, such as differences in ethnic prevalence, median age and alteration patterns. Consequently, beyond traditional chemoradiotherapy, molecular-targeted therapy and treatment with immune check-point inhibitors (ICI) also became available major therapeutic options. Interestingly, clinical results suggest that the recently established therapies target distinct lung cancer proportions, particularly between the EGFR/ALK and PD-1/PD-L1-positive subsets, e.g. the kinase inhibitors target driver mutation-positive tumours, whereas driver mutation-negative tumours respond to ICI treatment. These therapeutic efficacy-related differences might be explained by the molecular pathogenesis of lung cancer. Addictive driver mutations promote tumour formation with powerful transformation performance, resulting in a low tumour mutation burden, reduced immune surveillance, and subsequent poor response to ICIs. In contrast, regular tobacco smoke exposure repeatedly injures the proximal airway epithelium, leading to accumulated genetic alterations. In the latter pathway, overgrowth due to alteration and immunological exclusion against neoantigens is initially balanced. However, tumours could be generated from certain clones that outcompete immunological exclusion and outgrow the others. Consequently, this cancer type responds to immune check-point treatment. These pathogenic differences are explained well by the two-compartment model, focusing upon the anatomical and functional composition of distinct cellular components between the terminal respiratory unit and the air-conducting system. Two-compartment model in the putative molecular pathogenesis of lung cancer. The accumulation of genetic alterations with escaping immune surveillance is a key factor for tumours from the air-conducting system under the strong influence of tobacco smoke, whereas oncogene-addicted adenocarcinomas are driven by a single oncogenic mutation with powerful transformation activity.image
引用
收藏
页码:50 / 66
页数:17
相关论文
共 50 条
  • [41] Predictive immunocytochemistry in non-small cell lung carcinoma
    Brcic, Luka
    Prince, Spasenija Savic
    PATHOLOGE, 2022, 43 (03): : 222 - 228
  • [42] KRAS Amplification in Non-Small Cell Lung Carcinoma
    Stiedl, A. C.
    Wagner, P. L.
    Wilbertz, T.
    Altorki, N. K.
    Perner, S. R.
    LABORATORY INVESTIGATION, 2010, 90 : 414A - 414A
  • [43] Primary non-small cell neuroendocrine carcinoma of the ovary
    Strobel, SL
    Graham, R
    JOURNAL OF HISTOTECHNOLOGY, 2003, 26 (01) : 73 - 76
  • [44] Targeted Therapy in non-small cell Lung Carcinoma
    Tessmer, Antje
    Kollmeier, Jens
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2015, 140 (05) : 324 - 330
  • [45] CHEMOTHERAPY OF NON-SMALL CELL BRONCHOGENIC-CARCINOMA
    DIMITRIADIS, K
    BOUTIS, L
    TAVANTZIS, J
    MOURATIDOU, D
    BOUCHORIS, N
    KOUKOURIKOS, S
    HATZIGOGOS, K
    SAFARINI, S
    ONKOLOGIE, 1983, 6 (01): : 8 - 10
  • [46] Non-small cell bronchial carcinoma: optimisation of radiotherapy
    Belliere, A
    Girard, N
    Chapet, O
    Ardiet, JM
    Mornex, F
    REVUE DES MALADIES RESPIRATOIRES, 2005, 22 (06) : S124 - S130
  • [47] Palliative radiotherapy for non-small cell lung carcinoma
    Powell, J.
    Davies, S.
    Lester, J. F.
    Button, M. R.
    Brewster, A. E.
    Hanna, L.
    LUNG CANCER, 2010, 67 : S30 - S30
  • [48] Pulmonary infarct masquerading as a non-small cell carcinoma
    Le, Richard D.
    Schuller, Dan
    Bewtra, Chhanda
    CHEST, 2006, 130 (04) : 323S - 324S
  • [49] Genetic changes in non-small cell lung carcinoma
    Uvirova, M.
    Urbanovska, I.
    Konvalinka, D.
    Simova, J.
    Kubova, B.
    Jaluvkova, M.
    Zmolikova, J.
    Ziak, D.
    Dvorackova, J.
    VIRCHOWS ARCHIV, 2012, 461 : S172 - S172
  • [50] Emerging mitotic inhibitors for non-small cell carcinoma
    Casaluce, Francesca
    Sgambato, Assunta
    Maione, Paolo
    Ciardiello, Fortunato
    Gridelli, Cesare
    EXPERT OPINION ON EMERGING DRUGS, 2013, 18 (01) : 97 - 107